-
AbbVie JAK inhibitor shows potential in novel atopic dermatitis head-to-head trial
26 Apr 2024 13:06 GMT
… -head trial in atopic dermatitis assessing RINVOQ® (upadacitinib) … moderate-to-severe atopic dermatitis. The trial assessed … disease control in atopic dermatitis despite taking steps to … in previous upadacitinib atopic dermatitis clinical studies.
These results …
-
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
26 Apr 2024 05:59 GMT
… >1.
About Atopic Dermatitis
Atopic dermatitis is a chronic, relapsing inflammatory … alopecia areata, ankylosing spondylitis, atopic dermatitis, axial spondyloarthritis, Crohn's … With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1). …
-
Study Highlights Trends in Atopic Dermatitis Web Search Volume in Europe
25 Apr 2024 20:29 GMT
… crowdsourced web data regarding atopic dermatitis has been identified previously … most useful terminology for atopic dermatitis.
The team implemented professional … the research team regarding atopic dermatitis statistics, demonstrating substantial variation …
-
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
25 Apr 2024 18:26 GMT
… its labeled dose) for atopic dermatitis.
AbbVie said the study … to-head trial in atopic dermatitis assessing upadacitinib at a starting … with moderate-to-severe atopic dermatitis (AD) who had an … severity and extent of atopic dermatitis.
WP-NRS is an …
-
Upadacitinib Superior in Efficacy to Dupilumab for Atopic Dermatitis in Head-to-Head Study
25 Apr 2024 14:54 GMT
… for the treatment of atopic dermatitis, according to an announcement … moderate-to-severe atopic dermatitis and either an inadequate … disease control in atopic dermatitis despite taking steps to … treatment goals in atopic dermatitis with combined measures of …
-
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
25 Apr 2024 11:21 GMT
… animal models for obesity, atopic dermatitis, inflammatory pain, and alcoholic hepatitis … the oxazolone model of atopic dermatitis, RASP modulators ADX-629, ADX …
-
Patients with atopic dermatitis report year-long improvements with upadacitinib
24 Apr 2024 17:43 GMT
… to Healio
Patients with atopic dermatitis were treated once daily with … with moderate to severe atopic dermatitis treated with upadacitinib reported year … a study.
“Symptoms of atopic dermatitis, such as itch and sleep …
-
Dupilumab Linked to Increased Risk of Cutaneous T Cell Lymphoma in Atopic Dermatitis Patients: Study
23 Apr 2024 18:19 GMT
… with moderate to severe atopic dermatitis (AD), according to … moderate to severe atopic dermatitis. It works by targeting … in patients with atopic dermatitis was associated with an … ). Dupilumab therapy for atopic dermatitis is associated with increased risk …
-
ASLAN reports interim data from atopic dermatitis drug trial
23 Apr 2024 11:50 GMT
… for moderate-to-severe atopic dermatitis (AD) in adults.
The randomised …
-
Eblasakimab Shows Benefit in Atopic Dermatitis Among Dupilumab-Treated Patients
22 Apr 2024 21:38 GMT
… controlled trial conducted in atopic dermatitis patients previously treated with … study of dupilumab-experienced [atopic dermatitis] patients, and to optimizing … Eblasakimab in dupilumab-experienced atopic dermatitis patients. ASLAN Pharmaceuticals. April …